The below table is a good overview other investors may find useful (source: Perplexity AI)
Tryptamine Therapeutics stands out due to its innovative IV-infused formulation, which offers significant advantages over traditional oral psilocybin treatments. However, competitors like Compass Pathways are more advanced in clinical development, particularly with their ongoing Phase 3 trials. Though I think any success with competing Ph3 trials is an overall win for the industry and should actually de-risk TYP.
- Forums
- ASX - By Stock
- TYP
- On the world stage
TYP
tryptamine therapeutics limited
Add to My Watchlist
2.94%
!
3.3¢

On the world stage
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
3.3¢ |
Change
-0.001(2.94%) |
Mkt cap ! $45.85M |
Open | High | Low | Value | Volume |
3.5¢ | 3.5¢ | 3.2¢ | $55.80K | 1.669M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 9663 | 3.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.4¢ | 30000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 9663 | 0.033 |
2 | 213431 | 0.032 |
4 | 685166 | 0.031 |
5 | 534168 | 0.030 |
4 | 335299 | 0.029 |
Price($) | Vol. | No. |
---|---|---|
0.034 | 30000 | 1 |
0.035 | 640979 | 5 |
0.036 | 100000 | 1 |
0.037 | 470000 | 2 |
0.038 | 460847 | 3 |
Last trade - 13.22pm 08/09/2025 (20 minute delay) ? |
Featured News
TYP (ASX) Chart |